Logo

RNXT

RenovoRx, Inc.

RNXT

RenovoRx, Inc. • NASDAQ
$0.92 ▲ 3.52% (+0.03)
Market Cap $33.62 M
52w High $1.69
52w Low $0.70
Dividend Yield 0%
P/E -2.55
Volume 155.00K
Outstanding Shares 36.65M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $266K ▼ $3.413M ▲ $-2.912M ▼ -1.095K% ▼ $-0.08 ▼ $-2.911M ▼
Q2-2025 $422K ▲ $2.948M ▼ $-2.895M ▼ -686.019% ▲ $-0.079 ▼ $-2.677M ▼
Q1-2025 $197K ▲ $3.213M ▲ $-2.42M ▲ -1.228K% ▲ $-0.077 ▲ $-2.419M ▼
Q4-2024 $43K ▲ $2.675M ▼ $-2.878M ▼ -6.693K% ▼ $-0.13 ▼ $0 ▲
Q3-2024 $0 $2.828M $-2.471M 0% $-0.099 $-2.828M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.044M ▼ $11.206M ▼ $3.128M ▲ $8.078M ▼
Q2-2025 $12.314M ▼ $13.643M ▼ $3.002M ▲ $10.641M ▼
Q1-2025 $14.582M ▲ $16.014M ▲ $2.857M ▼ $13.157M ▲
Q4-2024 $7.154M ▼ $8.118M ▼ $3.64M ▲ $4.478M ▼
Q3-2024 $9.563M $10.031M $2.96M $7.071M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.912M ▼ $-2.27M ▲ $0 $0 ▼ $-2.27M ▼ $-2.27M ▲
Q2-2025 $-2.895M ▼ $-2.302M ▲ $0 ▲ $34K ▼ $-2.268M ▼ $-2.302M ▲
Q1-2025 $-2.42M ▲ $-3.381M ▼ $-2K ▲ $10.811M ▲ $7.428M ▲ $-3.383M ▼
Q4-2024 $-2.878M ▼ $-2.43M ▼ $-12K ▼ $33K ▲ $-2.409M ▼ $-2.442M ▼
Q3-2024 $-2.471M $-2.194M $0 $15K $-2.179M $-2.194M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Other Operating Segment
Other Operating Segment
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement RenovoRx’s income statement looks like a typical early-stage biotech: essentially no product revenue through 2024 and recurring losses driven by research and development and overhead. Earnings per share have been negative each year, reflecting this steady burn. The business is still in the “investment” phase, not the “profit” phase. The company has only recently begun to see early device sales according to the narrative, but historically its financial results have been dominated by expenses related to clinical trials and product development rather than income generation.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base mostly made up of cash and no reported debt. The absence of borrowings lowers financial risk from interest and repayments, but the modest cash and equity levels signal that RenovoRx does not have a large financial cushion. In practical terms, the company’s ability to fund trials and commercialization efforts will likely depend on its skill in raising additional capital, managing costs, and gradually growing device revenues, rather than drawing on a deep balance-sheet reserve.

Cash Flow

Cash Flow Cash flow data show a consistent pattern of money flowing out of the business to fund operations, with little or no offset from incoming cash tied to sales. Operating and free cash flow have been negative, and there is no meaningful spending on long-lived assets, so the primary use of cash is running the company and its clinical programs. This is typical for a clinical-stage biotech, but it also means RenovoRx’s future hinges on continued access to funding until its technology can generate meaningful, recurring cash inflows.

Competitive Edge

Competitive Edge RenovoRx competes in a crowded cancer-treatment landscape but occupies a fairly specialized niche. Its edge comes from a targeted delivery platform (TAMP) and the RenovoCath device, which aim to push chemotherapy directly into hard-to-treat tumors. The company benefits from FDA clearance for the device, orphan drug designations, and a growing patent portfolio, all of which help protect its position. It has a first-mover advantage in its specific delivery approach for locally advanced pancreatic cancer, backed by late-stage clinical work. However, it is a small player operating against much larger pharmaceutical and medical-device companies, and its long-term standing will depend heavily on clinical outcomes, physician adoption, and reimbursement decisions.

Innovation and R&D

Innovation and R&D Innovation is the core of RenovoRx. The TAMP platform and RenovoCath device embody a focused strategy: improve outcomes not by inventing new drugs, but by delivering proven drugs more precisely to tumors. The lead program, RenovoGem, is in a pivotal Phase III trial, which is a critical value- and risk-driver. Beyond that, the company is exploring use of its platform in other solid tumors, evaluating real-world outcomes through a registry study, and collaborating with partners like Imugene to deliver novel agents such as oncolytic viruses. Overall, RenovoRx is research-heavy with a clear technological theme and multiple potential applications if the underlying concept is validated.

Summary

RenovoRx is an early-stage oncology company built around a targeted drug-delivery platform rather than traditional systemic therapies. Financially, it remains in a pre-profit, historically near-zero-revenue phase with ongoing losses and steady cash burn, supported by a lean but debt-free balance sheet. Strategically, its strength lies in a differentiated delivery technology, intellectual-property protection, regulatory designations, and a lead program in late-stage development for a high-need cancer. At the same time, the business is exposed to typical biotech risks: dependence on a small number of key programs, trial and regulatory uncertainty, the need for ongoing external financing, and competition from much larger players and alternative technologies. The company’s future profile will be shaped largely by upcoming clinical results and its ability to turn early device adoption into a scalable, sustainable revenue base.

NEWS

November 19, 2025 · 8:30 AM UTC

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Read more

November 13, 2025 · 4:05 PM UTC

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Read more

November 6, 2025 · 8:30 AM UTC

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Read more

November 4, 2025 · 8:30 AM UTC

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Read more

October 27, 2025 · 8:30 AM UTC

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Read more